Introduction {#Sec1}
============

According to the free drug hypothesis only the unbound drug is available to act at physiological sites of action, whether it is the intended pharmacological target, or action at an undesired site with potential toxicological consequences. The importance of plasma protein binding primarily resides in its impact on pharmacokinetic properties such as clearance (CL) and volume of distribution (V~ss~), with serum albumin, lipoproteins and alpha-1 acid glycoprotein (AAG) being the major proteins involved in sequestering drugs in plasma ([@CR1]). AAG also known as orosomucoid (ORM), is a member of the acute phase protein (APP) family, first described in 1950 ([@CR2]). It has a single polypeptide chain consisting of 183 amino acids with five glycan chains, accounting for \~45% of its total molecular weight (\~41--44 kDa) ([@CR3],[@CR4]). AAG is formed primarily in the liver and circulates from 0.5 to 1.0 mg/ml in the plasma of healthy humans ([@CR3]). Levels in healthy animals are generally lower compared to healthy humans (Table [I](#Tab1){ref-type="table"}). In most disease states including inflammation, infection, and cancer, AAG levels increase from 2 to 6-fold in humans ([@CR3]), and show a much broader fold of induction in animals from 2 to 20-fold depending on animal species and disease (Table [I](#Tab1){ref-type="table"}). While the biological role of AAG remains unclear, it has been demonstrated to regulate immunity and play a role in both pro- and anti-inflammatory response ([@CR37],[@CR38]). AAG has long been used as a clinical biomarker, and the potential to expand its application for disease diagnosis, prognosis, and characterization has grown given the recent advances in proteomics and high resolution mass spectrometry ([@CR39]--[@CR42]).Table IAAG Levels in Plasma or Serum Across Species in Healthy and Disease StateSpecies/Strain or breedMean or range (mg/ml)Acute phase response/Disease typeReferenceHealthyDiseaseFold change disease/ HealthyMouse/C57BL/60.09--0.110.65--1.07--9Pulmonary Fibrosis([@CR5])Mouse/CD10.096Cancer, tumor load:([@CR6])0.3840.2--0.3 g (8d post implant)1.58 (1.35--1.81)14--190.8--1 g (15-20d post implant)Mouse/C57BL/60.12.020IL-1 mediated induction([@CR7])Mouse0.13.5\>20Acute phase response([@CR8])Mouse/CD1 & NMRI0.99--1.1([@CR9])Rat/Dark Agouti0.20 ± 0.011.38 ± 0.137Phenobarbital induced^b^([@CR10])Rat/Sprague-Dawley0.30 ± 0.040.49 ± 0.052Phenobarbital induced^b^([@CR10])Rat/Sprague-Dawley0.130.252Stress([@CR11])Rat/Lewis0.10.4--1.44--14Arthritis([@CR12])Rat/Wistar0.10.55Cirrhosis([@CR13])1.010Inflammation, LPS^c^Rat/Sprague-Dawley0.23--0.32([@CR9])Rabbit/New Zealand White0.31--0.41([@CR9])Pig/Conventional Crossbred2.51.40.6Infection([@CR14])1.51.10.7Inflammation0.34 ± 0.080.1--1.0≤3Arthritis([@CR15])0.9--1.2≤4Hernia0.2--2.0≤6Infection0.3--0.60.4--0.55noneInflammation, turpentine([@CR16])0.3--0.60.3--0.56noneInflammation, turpentine([@CR17])1.080.980.9Inflammation, LPS^c^([@CR18])Minipig/Ossabaw0.5([@CR14])Minipig/Gottingen0.3Minipig/Gottingen\~0.2\~0.2noneInflammation, LPS^c^([@CR19])0.3--0.4\~0.9 (0.6--1.5)2Obesity, High Fat Diet0.3--0.4\~1.0 (0.6--1.6)2Mild Diabetes, High Fat DietCat/Domestic0.27^a^0.83^a^3Cancer([@CR20])0.1--0.48≥ 1.53--15Infection([@CR21])0.230.512Cancer([@CR22])1.125Infection, Coronavirus3.8217Infection, Peritonitis0.24 ± 0.014.71 ± 1.476--19Inflammation/Diseased([@CR23])\<0.562.89 (2.04--14)\>3--25Infection([@CR24])0.27--0.38([@CR9])Dog/Beagle0.32 (0.04--0.96)1.21--1.361--34Infection([@CR25])0.371.634Inflammation([@CR26])0.25 (0.17--0.33)0.83 (0.5--1.3)2--7Infection([@CR27])0.472.856Inflammation([@CR28])0.501.944Infection([@CR29])0.37--0.60([@CR9])Monkey/Cynomolgus0.111.85--2.6716--24Inflammation([@CR30])5--10Infection^d^Human0.67 (0.45--1.12)2.20 ± 0.62 (1.03--3.15)2--3Cancer([@CR31])1.43 ± 0.65 (0.71--2.27)Infection0.50 ± 0.14 (0.28--0.92)([@CR32])0.46 ± 0.171.06 ± 0.562Pulmonary Fibrosis([@CR5])\~0.75\~0.9Renal Failure([@CR33])\~0.6Cirrhosis\~1.1Chronic Uremia\~1.5After Hemodialysis0.52 ± 0.24 (1--2 months)0.08--3.3 (0--1 month)0.2--7Infection -- Bacterial([@CR34])0.18--2.96 (0--1 month)Infection-Viral/Parasitological0.36--1.8Cancer([@CR35])0.77 ± 0.15 (0.36--1.46)([@CR36])0.5--1.0≤ 3.03--6Inflammation, infection, cancer([@CR3])^a^Median value^b^Independent of inflammation pathway^c^LPS Lipopolysaccharide (bacterial infection, acute inflammatory stimulus)^d^Life Diagnostics, Inc., indicated on package insert

While AAG represents a relatively small portion (\~1--3%) of the total plasma proteins, compared to \~60% composition of albumin, it can play a significant role in drug binding and pharmacokinetics (PK) ([@CR43]). AAG is considered a high affinity/low capacity plasma protein, whereas albumin is considered low affinity/high capacity. AAG is a highly acidic protein with a very low isoelectric point (pI) ranging from 2.8 to 3.8 ([@CR37]). This property enables AAG to bind mainly basic drugs (i.e. lidocaine, propranolol, verapamil) but it may also bind to neutral lipophilic molecules (i.e. steroid hormones) and to acidic drugs (i.e. phenobarbital), whereas albumin is mostly implicated in binding to the latter charge type ([@CR44],[@CR45]). Most drugs bind to both plasma proteins with varying degrees of affinity. The extensive and variable sialylation of AAG is what drives the low and wide pI range, a property that can impact drug affinity, and ultimately PK ([@CR3]). Since AAG levels increase in most disease states ([@CR46]), drugs with a high affinity may demonstrate higher binding (lower fraction unbound, f~u~) and altered PK properties (e.g. lower total CL), lower V~ss~. Given the known species differences in AAG abundance and drug affinity there is a growing body of work where PK in preclinical species did not accurately predict PK in human, and several of these case studies are discussed herein. Incorporating the ontogeny of AAG may also enable more accurate predictions of PK in neonate and infant patients ([@CR47]). We provide a rationale for testing the extent and affinity of drug binding to AAG and albumin in the drug discovery process to aid in prospective human PK prediction efforts (Fig. [1](#Fig1){ref-type="fig"}). Research is still lagging in the characterization of higher species AAG which could help better predict PK in human. Furthermore, there are experimental factors that are emerging as critical to the accurate determination of AAG-drug binding *in vitro*. These aspects are also discussed in this review.Fig. 1Proposed flowchart to ascertain impact of AAG as a potential covariate for PK variability in early drug development.

Biochemistry of AAG {#Sec2}
===================

Species {#Sec3}
-------

Albumin, AAG, and lipoproteins are considered the most relevant plasma proteins in terms of drug binding ([@CR1]). The range of albumin levels is slightly lower in animals compared to human. While levels of AAG are also relatively lower in most animals compared to human in the healthy state, levels are much more variable in the diseased setting as described below and in Table [I](#Tab1){ref-type="table"}. Human albumin and AAG levels in Table [II](#Tab2){ref-type="table"} provide units of mg/ml and μM to serve as a quick reference when considering stoichiometry with drug concentrations, assuming a single drug binding site model. Generally, in rodents (0.1--0.3 mg/ml) and mini-pigs (0.3--0.5 mg/ml) AAG values are lower compared to human (Table [I](#Tab1){ref-type="table"}). An exception to this generalization was reported in mice, however no explanation was suggested by the authors ([@CR9]). In dogs, AAG demonstrates highly variable levels (0.04--1 mg/ml) ([@CR25]), though generally lower mean values (0.25--0.5 mg/ml) have been reported ([@CR26]--[@CR28]). There is little characterization of monkey AAG in the literature, though it has also been reported to be lower in cynomolgus monkey (0.1 mg/ml) compared to human ([@CR30]). The conventional pig is the only species where AAG levels have been reported to be higher (1.1--2.5 mg/ml) ([@CR14],[@CR18]) compared to human. However, this finding has not been consistently observed, lower AAG values of 0.24 mg/ml ([@CR16]) and 0.34 mg/ml ([@CR15]) have also been reported in the conventional pig.Table IIAlbumin and AAG Concentration Ranges in Plasma of Healthy HumansProteinMW\
kDaConcentrationmg/mlμMAlbumin6735--50500--750AAG420.4--1.09--24

Disease State {#Sec4}
-------------

In most species, AAG behaves as a positive acute phase protein (APP), increasing in response to stimuli, including infection, inflammation, and cancer (Table [I](#Tab1){ref-type="table"}). The acute phase response (APR) is considered part of the innate (non-specific) defense system that offers protection prior to the adaptive (specific) immune response. The magnitude of response can differ across species and disease setting. Minor, moderate, and major AAPs are characterized by increases in protein expression by 0.25--1, 1--10, and \> 10-fold, respectively. In mice AAG is considered a major positive APP as levels increase up to 20-fold following stimuli ([@CR7],[@CR8]), whereas in human the response is relatively moderate with increases of \~2--6 fold ([@CR3],[@CR31]). In the domestic cat, AAG increases are moderate (\~2--3 fold) in the oncology setting, whereas a more robust response has been reported with infections (up to 17-fold) ([@CR20]--[@CR22]).

Mixed responses have been reported in the conventional pig and the minipig. In the conventional pig, AAG has been shown to behave as both a negative APP with levels declining to \~0.6--0.7-fold normal values ([@CR14]) and as a positive APP in response to infection and inflammation, with levels increasing 3--6-fold ([@CR15]). In both conventional pigs ([@CR18]) and minipigs ([@CR16],[@CR48],[@CR49]) there was no AAG response following acute stimuli (LPS or turpentine injection), despite increases in other APPs in the conventional pig (TNFα and IL-6) and in minipigs (C-reactive protein (CRP), serum amyloid A (SAA), haptoglobin (Hp), pig major acute phase protein (PMAP)). Christoffersen *et al.* ([@CR19]) hypothesized the AAG response in the minipig may have different sensitivity in the acute *versus* chronic setting, an observation previously reported for other APPs (SAA and Hp) in cattle ([@CR49]). In a chronic inflammatory setting, obese and mildly diabetic minipigs fed a high fat diet had elevated (\~2-fold) AAG levels ([@CR19]). Changing housing conditions also caused up to a 2-fold increase in AAG in minipigs (as well as increases in CRP, SAA, Hp and PMAP), and it is unclear when levels return to baseline, a finding that should be considered in acclimation, experimental design and data interpretation ([@CR19]). Neither the negative APP response nor LPS insensitivity of porcine AAG have been reported in any other species to date. However, it is not unprecedented for a given APP to behave differently across species. For example, while CRP and SAA are considered major positive APPs in human and pig, CRP and SAA are not affected in mice and rats, respectively. Another example of differential species response is with transferrin, which acts as a negative APP in human, and a positive APP in mice ([@CR19],[@CR48]).

Gender {#Sec5}
------

There have been mixed reports regarding gender differences in AAG levels. While there may be statistical differences, they are relatively modest compared to the differences observed in disease or developmental settings. Booker *et al.* ([@CR50]) reported statistically significant differences in AAG levels between newborn human males (0.42 mg/ml) and females (0.33 mg/ml) (Table [III](#Tab3){ref-type="table"}). The opposite trend was observed in adult humans; AAG levels of 0.39 and 0.50 mg/ml in males and females, respectively ([@CR51]). Similarly, Blain *et al.* ([@CR36]) reported slightly lower levels in human males (0.74 mg/ml) compared to female (0.84 mg/ml). Female minipigs generally have slightly lower, though overlapping ranges, of AAG levels compared to males ([@CR19]). No gender difference was observed in dog AAG levels (0.32 mg/ml) ([@CR25]).Table IIIAAG in Plasma or Serum Across Gender in Healthy SubjectsSpecies/StrainMean or range (mg/ml) ± Standard deviationReferenceMaleFemaleMinipig/Gottingen0.29 (0.23--0.42)0.41 (0.32--0.56)([@CR19])Dog/Beagle0.32 (0.04--0.96)0.32 (0.05--0.83)([@CR25])Human0.74 ± 0.170.84 ± 0.18([@CR36])0.39 ± 0.080.50 ± 0.07([@CR51])0.42 ± 0.170.33 ± 0.14([@CR50])0.62 ± 0.120.67 ± 0.13([@CR52])

Ontogeny {#Sec6}
--------

AAG levels range from undetectable in the developing human fetus, to 0.1--0.2 mg/ml in cord blood ([@CR47],[@CR51],[@CR53]), up to 0.3 mg/ml at birth ([@CR34],[@CR51],[@CR54]--[@CR57]), steadily increasing to 0.4--0.7 mg/ml at 2--3 months ([@CR34],[@CR50],[@CR55]), and achieving adult levels (0.6--0.9 mg/ml) by 10--12 months of age ([@CR33],[@CR34],[@CR58]) (Table [IV](#Tab4){ref-type="table"}). Similarly, AAG is undetectable (\<0.04 mg/ml) in the cord blood of dogs, thus significantly lower compared to adult dogs (0.32 mg/ml) ([@CR25]). The opposite trend was observed in conventional pigs, with 12.7 mg/ml reported in the fetal pig, 14.3 mg/ml in 1 day newborns, 0.70 mg/ml in 4 week olds, and 0.24--0.34 mg/ml in adults ([@CR15],[@CR16]). Consistent with this pattern, Heegaard *et al.* ([@CR14]) reported AAG levels of 6.6 mg/ml in newborn pigs (5--6 days old) that declined to 1.1 mg/ml in adults. AAG comprises about 50% of the total plasma proteins in the newborn pig, whereas only about 0.3% in the adult pig. This property has not been reported in mini-pigs or any other laboratory animal to date. Limited data have been published on fetal and neonatal plasma levels of AAG in other species. However, liver AAG levels in rat have also been shown to vary in development ([@CR60]).Table IVOntogeny and Impact of Pregnancy on AAG Protein Levels in Plasma or SerumSpecies/StrainAAG mean or range (mg/ml) ± Standard deviation / Age or pregnancy statusReferenceFetus/AgeNewborn/AgeAdult/Age or pregnancy statusMinipig/Gottingen0.34 (0.25--0.53)/6 weeks0.29 (0.23--0.41)/40--48 weeks([@CR19])0.41 (0.34--0.47)/16 weeks0.33 (0.26--0.38)/24 weeksMinipig/Gottingen0.3/14--16 months([@CR14])Minipig/Ossabaw0.5/41--47 monthsPig/Conventional crossbred (Landrace Yorkshire)0.6/8--9 months([@CR14])Pig/Conventional crossbred (Duroc Yorkshire Landrace)6.6/2--5 days1.1/26--31 daysPig/Conventional crossbred (Landrace White)14.3 ± 2.4/1 days0.34 ± 0.08/5--10 months([@CR15])6.1 ± 1.6/4 days1.3 ± 0.5/2 weeks12.70.24([@CR16])Dog/Beagle\<0.04/cord0.32 (0.04--0.96)/male([@CR25])0.32(0.05--0.83)/female0.63 (0.25--1.0)/pregnant femaleMonkey/Rhesus0.43--0.52/pregnancy 13--18 weeks([@CR59])0.70/pregnancy 19 weeks0.90/pregnancy 21 weeks1.35/pregnancy 22 weeks1.90/pregnancy 24 weeks1.55--1.70/postpartem 1--3 daysHuman0.14 ± 0.20/cord neonate0.65 ± 0.13/pregnancy trimester 1([@CR53])0.51 ± 0.24/pregnancy trimester 20.44 ± 0.12/pregnancy trimester 30.89 ± 0.20/postpartum mother0.64 ± 0.10/non-pregnant femaleBLQ--0.15/12--23 weeks0.50--1.05/pregnant female 12--23 weeks([@CR56])0.06--0.33/27--34 weeks0.08--0.41/35--41 weeks0.38--0.99/pregnant female 27--34 weeks0.29--0.88/pregnant female 35--41 weeks0.05 (0.02--0.2)/19--34 weeks0.7 (0.45--0.9)/non-pregnant female([@CR57])0.55 (0.35--0.8)/pregnant female0.08 (0.01--0.1)/amniotic fluid0.24/cord neonate0.60([@CR47])0.1--0.3/neonate0.7--2.5/postpartum mother([@CR54])0.34 ± 0.15/30--36 weeks([@CR58])0.46 ± 0.19/1--12 months0.66 ± 0.28/1--5 years0.63 ± 0.16/12--18 years0.13--0.20/birth0.94 ± 0.22/2 years([@CR34])0.52 ± 0.24/1--2 months0.84 ± 0.18/3--4 years0.58 ± 0.25/2--3 months0.88 ± 0.21/5--9 years0.82 ± 0.20/10 months0.42 ± 0.17/7 weeks male([@CR50])0.33 ± 0.14/10 weeks female0.250.7([@CR33])0.15 ± 0.05/cord0.50 ± 0.07/pregnant female([@CR51])0.50 ± 0.07/non-pregnant female0.39 ± 0.08/male0.28^a^ (0.13--0.56)^b^/birth0.83^a^ (0.52--1.26)^b^([@CR55])0.48^a^ (0.31--0.93)^b^/1 month0.67^a^ (0.41--0.97)^b^/3 months0.70^a^ (0.43--1.49)^b^/6 months*BQL*, below limit of quantitation^a^50^th^ percentile values^b^5^th^, 95th percentile values

Pregnancy and Placental Transfer to Milk {#Sec7}
----------------------------------------

Pregnancy can also impact AAG levels. In human AAG levels are lower in the pregnant female and continue to decline throughout pregnancy until birth when they begin to climb back to pre-pregnancy values ([@CR53],[@CR56],[@CR57]). Wood and Wood ([@CR51]) reported the same values in female non-pregnant healthy volunteers and pregnant women, however the study size was relatively small (*n* = 10). The opposite has been reported in the pregnant dog ([@CR25]) and in rhesus monkey ([@CR59]), with AAG levels about 2-fold and 4-fold higher in the pregnant animal, respectively.

Given the striking differences between fetal, newborn, and adult AAG levels, it may be important to understand placental transfer and the milk to plasma ratio (M/P) for drugs that bind to AAG. Fleishaker and McNamara ([@CR61]) described a diffusional model to assess drug distribution in milk, showing that the *in vitro* drug binding to serum and milk protein reasonably predict M/P drug ratio *in vivo*. The same authors tested the model in lactating rabbits using propranolol, a compound known to bind with high affinity to AAG. To mimic the disease setting, rabbits were dosed with bovine AAG and propranolol PK parameters were evaluated. The diffusional model was able to accurately predict the decrease in propranolol M/P from 2.13 to 1.23 before and after AAG administration. Importantly, a roughly proportional reduction in total plasma CL (35%) counteracted the decrease in f~u~ (22%), maintaining consistent CL~u~ rate and total drug levels in milk.

To improve the prediction of f~u~ in human infants McNamara and Alcorn ([@CR47]) considered the ratio of AAG and albumin in cord blood of newborns and adult blood. The corresponding ratios for AAG and albumin employed were 0.38 (0.24 mg/ml cord divided by 0.60 mg/ml adult) and 0.81 (36 mg/ml cord divided by 45 mg/ml adult). Prediction of f~u~ in newborns was better for drugs that predominantly bind to albumin. The average predicted and observed ratios (newborn/adult), of f~u~ were 1.20 and 1.38, respectively, for drugs that predominantly bind to albumin (*n* = 28 drugs in study set). The average predicted and observed ratios (newborn/adult), of f~u~ were 1.61 and 2.50, respectively, for drugs that predominantly bind to AAG (*n* = 11 drugs in study set). For the majority of drugs, the f~u~ in newborns was under-predicted, 10/11 and 22/28 drugs that predominantly bind to AAG and albumin, respectively. Possible explanations for the disparity suggested by the authors include changes in drug-ligand affinity associated with age as well as increased free fatty acids and bilirubin in the newborn that can contribute to decreased drug binding. In addition, the under prediction may be due to inaccurate (falsely high) AAG and albumin newborn levels employed in the model. While AAG levels are generally more variable (higher dynamic range) compared to albumin, this alone cannot explain the trend in under prediction.

Structure and Genetics of Human AAG {#Sec8}
===================================

Three genes (AAG-A, AAG-B, and AAG-B′), located on chromosome 9, encode human AAG (hAAG) ([@CR37]). AAG-A encodes ORM1 and is expressed in the liver at \>100-fold that of AAG-B and AAG-B′. AAG-B and AAG-B′ are identical in structure, differ from AAG-A by 22 amino acids, and encode ORM2 ([@CR62]). AAG shares significant homology with human immunoglobulin G (IgG) and the epidermal growth factor (EGF)-binding domain of the EGF receptor ([@CR63],[@CR64]).

AAG-A (ORM1) is polymorphic with three closely related genetic variants: F1, F2, and S, differing by \<5 amino acid residues, and generally referred to as F1\*S in Table [V](#Tab5){ref-type="table"} ([@CR65],[@CR66]). AAG-B and AAG-B′ (ORM2) encode the genetic variant A. Most individuals possess a mixture of these variants ([@CR67]). F1 + S + A is the most common phenotype (50%), followed by F1 + A (35%) and S + A (15%). The molar ratio of F1\*S to A is \~2--3:1 in healthy individuals ([@CR67]). The ratio can increase up to 8:1 in the disease setting since the F1\*S variant is inducible ([@CR68]). No gender related differences have been observed in expression of these variant forms ([@CR32]). X-ray crystallography showed two common binding pocket lobes between the F1\*S and A variants, while the F1\*S variant possesses a unique third lobe making it more promiscuous for drug binding ([@CR69],[@CR70]). Drug binding properties have been shown to differ amongst these variants ([@CR71]). For example, the basic drug imipramine was shown to bind more strongly to A variant, whereas warfarin more strongly to the F1 and S variants. For most drugs, binding to genetic variants has not been well characterized since protein binding studies are routinely conducted on a pooled supply of healthy human plasma or in the whole plasma of individual subjects/patients.Table VGenetic Variants of Human AAGGene^a^Protein^a^Collective variantIndividual variantBinding pocket lobesDrug binding selectivityVariant molar ratio (F1\*S/A)HealthyDiseaseORM1AAG-AF1\*SF1I, II, IIIlower2--3up to 8F2SORM2AAG-BAAI, IIhigher11AAG-B′AReferences ([@CR65],[@CR66])^a^Gene and protein nomenclature used interchangeably in literature

Proteins routinely undergo post-translational modifications that can impact physiological function and half-life (t~1/2~). Glycosylation, the addition of oligosaccharide chains (glycans) is one of the most abundant post-translational modifications, with an incidence of \~50% in eukaryotic proteins ([@CR72]). AAPs are particularly susceptible to glycosylation. Glycosyltransferases and glycosidases are responsible for building the precursors to glycans, a process highly vulnerable to changes in disease state ([@CR73]). Oligosaccharyltransferases then transfer glycans to the polypeptide chain at asparagine (N-linked) or serine/threonine (O-linked) residues, the former of which exhibit a common pentasaccharide core. The glycan bonds occur in either α or β configuration allowing for more structural diversity. The anti-inflammatory and immunomodulatory properties are directly impacted by glycan composition which, in turn, changes throughout the various stages of inflammation.

The heavily sialylated glycans make AAG one of the most acidic plasma proteins. There is a high level of heterogeneity resulting in a very low but wide pI ranging from 2.8 to 3.8 which in turn can impact drug binding and AAG t~1/2~ ([@CR37]). Desialylation can result in an increase in pI range from 4.2 to 4.7 ([@CR74],[@CR75]). Human AAG contains 5 N-linked glycans of the polypeptide backbone, each of which can form a variety of bi, tri, or tetra-branches all potentially further expressing sialic acid moieties ([@CR65]). Despite thousands of potentially unique glycan combinations associated with AAG, only about 12--20 glycan combinations are observed in the plasma of healthy humans ([@CR37],[@CR76]). However, in the disease state many more glycan modifications have been detected under the regulation of inflammatory cytokines, tumor necrosis factor (TNFα), interleukin-1 (IL-1) and IL-6 and its utility as a biomarker will be described later ([@CR76]). AAG offers two drug binding sites for basic drugs, one for acid drugs ([@CR44]), and up to 7 for steroids ([@CR45]). Drug binding to AAG is reportedly mediated predominantly via hydrophobic interaction with some data suggesting potential for electrostatic interaction. Evidence to support the latter includes the observation of stereoselective binding in propranolol isomers ([@CR77]). Desialylation and lower plasma pH have been shown to decrease drug binding to AAG ([@CR78],[@CR79]). Propranolol binding was reduced and progesterone binding unchanged with desialylated AAG.

Homologous AAG genes have been observed across mammals including rodents, cats, dogs, pigs, monkeys and humans (Table [VI](#Tab6){ref-type="table"}). Mouse, rat, rabbit, and pig AAG genes share \~44%, 59%, 70% and 70% homology, respectively, with human AAG ([@CR37],[@CR80]). While there are three human AAG genes, there is only one gene reported in rat and two to three in mouse depending on strain or source. Despite the presence of multiple genes, only one gene is associated with the positive APP ([@CR86],[@CR87]). AAG is comprised of 183 amino acid residues in human and 183--194 in animals. There are 5--6 asparagine (N)-linked glycans in human and rodents, most of which are highly conserved at positions 15, 38, 54, 75, and 85 in humans ([@CR88]) and 16, 58, 75, and 86 in rodents ([@CR81]). Two disulfide bridges have been described in human and pig AAG, with only one in rat. Various binding sites have been characterized across species; in human acidic, basic, and steroid binding sites have been reported, whereas cows and dogs lack the acidic binding site ([@CR4]).Table VIAAG Characterization and Homology Across SpeciesSpeciesGenesAmino acidsN-linked glycansMW\
kDaDisulfide bridgesIsoelectic pointBinding sites% Homology to humanReferenceMouse432.7([@CR43])Mouse34444([@CR80])Mouse21875--644([@CR81])Mouse318940--4647^a^Rat1187640--44159([@CR37],[@CR82])Rat1([@CR60])Rabbit19470([@CR83])Pig118354323.1--3.5([@CR15])Pig154323.6--4.370([@CR14])404.3--4.5Pig570([@CR84])CowBasic, Steroid([@CR4])DogBasic, Steroid([@CR4])Dog1443.5--3.8([@CR85])Human33.7--3.7([@CR85])Human3183541--442Acid, Basic Steroid([@CR4],[@CR37])Human2.8--3.8([@CR66])[^a^Rndsystems.com](http://arndsystems.com)

Regulation and Endogenous Function of AAG {#Sec9}
=========================================

AAG belongs to a family of APPs mainly generated in liver parenchymal cells at elevated levels within 12--24 h of injury (i.e. infection, inflammation, burns, cancer). APPs by definition are proteins that change in response to injury by \>25% in plasma ([@CR89]). Examples of positive APPs include ceruloplasmin, AAG, and serum amyloid A (SAA), all increasing levels in humans by about 50%, 3-fold, and \> 1000-fold, respectively, in the diseased state ([@CR90]). Negative APPs include albumin, transferrin, and insulin-like growth factor I, which modestly decline in plasma in the diseased state. AAG is a member of lipocalins, a superfamily of extra-cellular transporters that bind and transport small hydrophobic endogenous and exogenous chemicals. Upregulation of APPs enhances local inflammation by aiding in recognition of microbes, directing leukocytes, and increasing blood flow to the site of insult while minimizing inflammatory responses elsewhere ([@CR91]). The rapid and high magnitude of response, as well as the short t~1/2~, are properties characteristic of APPs and hypothesized to be key elements in innate immunity. Homeostasis is kept in check with redundancy such that a given APP may impact multiple pathways while multiple APPs may provide overlapping biological function. The inflammatory cytokines, TNFα, IL-1 and IL-6, have been shown to regulate AAG, in addition to the other APPs including C-reactive protein (CRP), haptoglobin (Hp), SAA and hemopexin ([@CR92]).

The function of AAG is still poorly understood, however, as part of a cytokine mediated feedback mechanism it has been implicated in both anti- and pro-inflammatory modulation ([@CR37],[@CR38]). Monocyte activation and induction of T-cell proliferation ([@CR93]) as well as activation of TNFα, IL-1 and IL-6 secretion ([@CR94]--[@CR96]) have been associated with the pro-inflammatory role of AAG. Su *et al.* ([@CR97]) proposed a positive feedback mechanism of APPs whereby inflammation is amplified in response to TNFα-mediated synthesis of AAG-stimulated monocytes and vice-versa. The anti-inflammatory role of AAG has also been reported. AAG inhibits neutrophil chemotactic response associated with stimulation of *N*-Formylmethionyl-leucyl-phenylalanine (fMLP) and the inflammatory peptide complement component C5a ([@CR98],[@CR99]). AAG was shown to modulate release of free radicals regardless of treatment time, whether AAG was introduced prior to or post neutrophil activation ([@CR100]). Multiple *in vivo* septic shock models in rodents have demonstrated the protective effect of AAG when dosed prophylactically to animals challenged by TNFα or endotoxin ([@CR101]).

The role of AAG in angiogenesis was studied using an ex vivo rat model ([@CR102]). Following aortic excision, macrophages respond by rapidly (within minutes) increasing TNFα levels, peaking at 24 h, and remaining elevated throughout angiogenesis. TNFα guides overexpression of AAG within 24 h, with levels peaking after 2--3 days and sharply declining thereafter. As with inflammation, AAG (and TNFα) has both pro- and anti-angiogenic effects depending on the context. Early in the angiogenesis process, AAG plays an inhibitory role via modulation of mitogen-activated protein kinases, whereas later in the process AAG promotes angiogenesis via vascular endothelial growth factor regulation.

Impact of Disease State on AAG Properties and Utility as a Biomarker {#Sec10}
====================================================================

As an APP, levels of AAG typically increase within 24 h of injury and begin to decline several days post amelioration. Increased AAG levels have been reported in the serum of breast, lung, and ovarian cancer patients ([@CR103]). In a study comparing AAG levels in lung cancer patients *versus* individuals with no known cancers, results showed 89% sensitivity and 85% specificity and AAG levels correlated with relapse-free survival ([@CR104]). In the case of hepatocellular carcinoma (HCC), diagnosis can be challenging due to other liver conditions (i.e. cirrhosis) presenting similar abnormalities, however increased AAG levels are more pronounced with HCC providing a potential basis to differentiate these diseases ([@CR105]). The proportion of breast cancer patients with increased AAG levels increases with disease progression, for example 25% and 81% of stage II and IV patients respectively, had elevated levels compared to 12% in healthy donors ([@CR106],[@CR107]).

In most disease states, AAG is modified both quantitatively as described above, as well as qualitatively, a phenomenon described by Alminquist and Lausing ([@CR39]) after comparing serum glycoproteins of cancer patients *versus* healthy donors. Relative to the associated polypeptide backbone, the heterogeneity in glycan composition and structure make it a good system for characterization and correlation with disease state ([@CR73]). Some commonly exploited glycoproteins used in clinical cancer biomarker tests include carcinoembryonic antigen (CEA), cancer antigen 125 (CA-125), CA-19-9, and prostate-specific antigen (PSA), for the diagnosis of colorectal, ovarian, pancreatic and prostate cancers, respectively. Technological advances in mass spectrometry and proteomics have led to an improved understanding of glycan structure and function. Glycans are relatively more abundant compared with their associated proteins, often times multiple copies per glycoprotein, as is the case for AAG known to have 5--6 associated glycans depending on species (Table [VI](#Tab6){ref-type="table"}). Not only are they associated with the cancerous tissue but they can also be detected in serum, making its use as a biomarker more feasible in the clinical setting. In addition, the same modified glycan may be associated with more than one glycoprotein affording multiple opportunities/patterns for detection. Modifications of the glycans associated with these biomarkers are relatively more specific and selective than the epitope itself, allowing for more accurate means for distinguishing healthy *versus* diseased tissue, and disease progression ([@CR40]). For example, testing serum levels of modified glycans associated with PSA enable the distinction between benign prostatic hypertrophy and cancerous prostate ([@CR41]). In breast cancer, the serum glycosylation pattern not only distinguishes healthy from diseased tissue but also differentiates between malignant and non-malignant tumors and disease stage ([@CR73]). In inflammatory diseases including rheumatoid arthritis and asthma, AAG glycans are more branched compared to healthy subjects ([@CR42]). Patients suffering from acute inflammation, infection, burns, and tissue damage all showed an asialylated carbohydrate-deficient variant of AAG ([@CR37]).

Human AAG t~1/2~ is relatively short, \~2--5 days ([@CR108],[@CR109]), compared to albumin, 14--21 days ([@CR110]). AAG turnover is dependent on sialic acid residues and terminal galactose groups. McCurdy ([@CR111]) studied the impact of glycosylation on *in vivo* CL of human derived AAG in rabbit following intravenous injection. The terminal t~1/2~ of native human AAG was 58 h (consistent with the t½ value of 69 h reported by Regoeczi *et al.* ([@CR112]). Altered/reduced or absence of glycosylation lowered the t½ to 50 h and 42 h, respectively. CL of native AAG was 2.2 ml/h/kg, whereas much higher values were observed for AAG forms with altered (11 ml/h/kg) or absent glycosylation (100 ml/h/kg). The steady-state volume of distribution (V~ss~) was 160 ml/kg for native AAG, whereas much higher values were observed with altered (550 ml/kg) or absent glycosylation (2000 ml/kg). The absence, reduction or alteration of N-linked glycosylation resulted in a marked increase (\>10-fold) in renal elimination compared to native AAG. These studies support that the dispositional properties of AAG are dependent on disease state since the biochemistry of AAG is altered with disease as described earlier. Therefore, if a given drug binds to AAG to a high extent, it is possible underlying differences in the PK of the drug between healthy and diseased populations may be attributable to AAG.

Impact of Plasma Protein Binding on Pharmacokinetics {#Sec11}
====================================================

Drug binding to plasma, tissue(s) and intended target are critical parameters to predict PK and pharmacodynamics (PD). However, optimizing protein binding to plasma in the drug discovery setting is scientifically unsound ([@CR113],[@CR114]). Nearly 30% of the 260 FDA approved drugs prior to 2003 are classified as highly bound (\>95% or f~u~ \< 0.05), and this trend has increased in recent years with 45% of new drugs classified as highly bound, 24% of which have f~u~ \< 0.01 ([@CR115]). While the free drug hypothesis describes that the free concentration drives activity as it can cross cellular membranes to reach its target, the focus should be to optimize CL~u~ and permeability.

As described above, albumin, AAG, and lipoproteins are considered the most important plasma proteins involved with drug binding. While albumin has a higher drug capacity due to its relative abundance in plasma, AAG levels are lower and with high affinity drugs saturation may occur. The saturation of AAG may or may not be buffered by albumin depending on the drug binding affinity for albumin. Plasma protein levels can change with disease state, a decrease in albumin and an increase in AAG are generally observed, which may impact protein binding and PK. Both albumin and AAG levels are significantly lower in the newborn, with newborn:adult ratios of about 0.81 and 0.38, respectively ([@CR47]), a factor that should be considered when predicting PK in the very young pediatric population.

A proposed flowchart to ascertain the impact of AAG as a potential covariate for PK variability early in drug development is shown in Fig. [1](#Fig1){ref-type="fig"}. Routine screening in human and laboratory animal species at a single low concentration (1--2 μM) is typically performed in early drug discovery as PK data in preclinical species is acquired. As a program advances towards development candidate selection with preliminary projections of human PK and dose, there is value in assessing concentration dependency and the identity of the major plasma proteins involved in drug binding. If the extent of binding is high (\>90% bound) under single concentration assay conditions, further characterization of the binding constants for AAG and albumin is warranted particularly if human free fraction is lower relative to animals or if concentration dependency is observed. If there is high affinity to human AAG it may be worthwhile to assess K~D~ in other species to build additional confidence in human PK predictions.

Considerations for Plasma Protein Binding Assays {#Sec12}
================================================

Multiple routine *in vitro* analytical procedures exist to assess the extent and affinity of drug binding to proteins. A recently published industry white paper (Di *et al.*, 2017) provides a comprehensive review of commonly used protein-binding practices, challenges, and recommendations ([@CR116]). The intention in this section of the manuscript is to suggest use of control compounds and to describe a source for erroneous fraction unbound values that has been overlooked.

Control Compounds {#Sec13}
-----------------

As with any assay it is good practice to include control compounds that are assessed along with test compounds to ensure a properly functioning assay. If data for control compounds are not available for a given assay/species one can still monitor the value for the control over time to ensure its consistency. When conducting definitive assays the use of multiple control compounds is advised since multiple factors can influence binding and some are compound specific. Literature values for propranolol and warfarin are summarized across species in Table [VII](#Tab7){ref-type="table"}. The intent here is to provide references for acceptable free fraction values for control compounds across species. Propranolol was selected because it has moderately high binding to human plasma proteins, however the affinity is higher for AAG relative to albumin by approximately two orders of magnitude ([@CR125]), therefore, propranolol can serve as a control for compounds that preferentially bind to AAG. The reported propranolol f~u~ values range from 0.10 to 0.29 in human plasma, a 3-fold difference, and outside what is typically deemed normal assay variability. The acceptable assay f~u~ value for propranolol should be within 0.10 to 0.20 in healthy human plasma. Warfarin was selected because it is highly bound to both AAG and albumin ([@CR126], GE life sciences application note 29263246AA). It is helpful to include a highly bound control compound since they generally require longer incubation time to achieve equilibrium. While the reported warfarin f~u~ values range from 0.005 to 0.022 in human plasma, more than a 4-fold difference, the absolute difference is low. The majority of references indicate a narrower range, therefore the acceptable assay f~u~ value for warfarin should be within 0.005 to 0.015, a range similar to that reported in the recently published white paper ([@CR116]). It is not advised to select a compound with moderate or low protein binding to serve as a control because the f~u~ values are generally more variable.Table VIIReported Plasma or Serum Protein Binding Values for Propranolol and WarfarinSpeciesDrug μMf~u~ mean or rangeReference, meeting or websitePropranololWarfarinMouse10.10--0.11([@CR117])100.170.07^a^100.150.06^b^Rat^h^0.010--0.018([@CR117])0.040.08([@CR118])10.210.005^c^10.003--0.004^d^10.280.005([@CR119])50.06^e^100.190.01^a^100.150.007^b^Rabbit^h^0.042--0.052([@CR117])0.040.35([@CR118])0.22--2.50.34([@CR120])Dog^h^0.040([@CR117])0.040.10([@CR118])10.270.038^c^10.200.033([@CR119])100.230.04^a^100.200.046^b^Guinea pig100.170.02^a^Minipig100.180.03^a^Monkey10.21([@CR121])10.210.005([@CR119])100.200.01^c^Human^h^0.012--0.022([@CR117])0.040.10([@CR118])^hi^0.10^fhi^0.01^g^10.210.006([@CR119])10.14([@CR121])10.130.011^c^10.160.005--0.006^d^10.29([@CR122])10.13([@CR123])1-3^i^0.005([@CR124])50.27^e^100.12\<0.01^a^100.190.007^ba^BD Biosciences brochure (now Corning), *In vitro* ADME discovery screening services, plasma protein binding using rapid equilibrium dialysis^b^BD Biosciences (now Corning) Application Note 474, 2009, Shanler M, Mason A, Crocker R, Vardaro R, Crespi C, Stresser D, Validation of an automated high throughput plasma protein binding assay^c^[www.noabbiodiscoveries.com](http://www.noabbiodiscoveries.com) website^d^Pierce Biotechnololgy, Inc., [www.piercenet.com](http://www.piercenet.com), Li S, Xiong B, Huang T, Li L, Donovan J, Lee F, Yu S, Miwa G, and Yang H, Validation of a novel rapid equilibrium dialysis (RED) device for high throughput plasma protein binding determination, 2006^e^Waters Corporation Application Note 720002610, Shave D and Alden P, Determination of protein binding by UPLC/MS/MS^f^Wyeth Package Insert, 2912389^g^Bristol-Myers Squibb Package Insert, 3022954^h^drug concentration not indicated^i^Values reported from ex vivo plasma samples

Effect of Plasticizers on Drug-Protein Binding {#Sec14}
----------------------------------------------

Based on recent studies ([@CR129],[@CR130]) it is possible the large range in human f~u~ values is due to the blood collection and storage procedure. In the clinical setting, f~u~ is typically measured in the plasma or serum of patients from blood collected in vacutainers. The collection procedure and storage of blood can have a significant impact on protein binding results. It has long been reported that plasticizers can disrupt the binding of drugs to AAG ([@CR131]--[@CR133]). For example, the plasticizer Tris (2-butoxyethyl) phosphate (TBEP), used to soften rubber stoppers in vacutainers, was shown to disrupt AAG binding to the basic drugs lidocaine and quinidine ([@CR134]). Polyvinyl chloride (PVC) bags containing the plasticizer diethylhexyl phthalate (DEHP) are routinely used in blood collection. Butler *et al.* ([@CR129]) reported an average of a two-fold increase in f~u~ for drugs known to bind to AAG when blood was collected in these PVC bags *versus* blood collected in vacutainers. More recently, experiments were conducted to show the correlation between DEHP levels and change in f~u~ with drugs that bind to AAG ([@CR130]). When blood was immediately transferred from Terumo® bags to vacutainers the DEHP levels were low (1--10 μM) but steadily increased with storage after 7 days (up to 300 μM) and 28 days (300--1000 μM). DEHP can easily leach into the contents of bags since it is not chemically bound to the PVC. As expected, f~u~ was higher (2--5-fold) with drugs known to bind to AAG when tested using plasma containing high levels of DEHP. The shift in f~u~ was significantly reduced, though not eliminated, when the blood was immediately transferred to vacutainers.

Results generated using blood products collected/stored in plasticizer containing bags should be interpreted with caution as the f~u~ values may over-estimate true *in vivo* values. In most instances when protein binding is measured clinically, vacutainers (no/minimal DEHP exposure) are used since small (\<10 ml) blood volumes are collected. This is in contrast to the relatively larger volumes (up to 350 ml) collected in bags for donation and/or non-clinical research purposes. It should be noted that the blood from animals is typically collected in smaller vessels not containing DEHP, therefore the over-estimation of f~u~ is less likely to occur in animal blood. Studies may be warranted to assess effects on drug binding with other commercially available vacutainers as a precaution. Despite what has been reported in the literature for decades, bags containing plasticizers known to disrupt AAG-drug binding continue to be widely used for blood collection with the intended use in both research and in the clinical setting. DEHP is essential in maintaining the shelf life of blood products up to 42 days as it protects the membrane of the red blood cell ([@CR135]). Transfusion recipients routinely receive blood that has been collected and stored in these bags. Clinical effects with regard to drug displacement have not been reported. Other blood collection bags have been developed though it is unclear if they have an effect on AAG-drug binding.

Examples Where AAG Binding Influences Pharmacokinetics {#Sec15}
======================================================

Multiple classes of drugs have been reported to bind to AAG. Examples of the relationship between AAG binding and lipid solubility and/or electrostatic interactions have been reported for benzodiazepines, phenothiazine neuroleptics, beta blockers, anthracycline derivatives, antihistamines, and analgesics ([@CR3],[@CR126]). Here we focus on several well-studied examples where the drug-AAG binding affected PK and/or PD in the clinical oncology setting.

Vismodegib {#Sec16}
----------

Vismodegib was approved for the treatment of metastatic basal cell carcinoma by the Food and Drug Administration (FDA) in 2012. PK characteristics exhibited in the phase I clinical trial were unexpected based on preclinical allometric scaling. Following a single oral dose, exposure was higher than predicted with a very low apparent CL and a long t~1/2~ of about 10--12 days ([@CR136]). Cross species *in vitro* data showed high plasma protein binding (≥95% bound) and low metabolic turnover in hepatocytes of all species except monkey, which agreed well with *in vivo* CL values ([@CR137]).

Mechanistic PK modeling was employed to explain the roles of plasma protein binding, solubility-limited absorption, and low metabolic CL in contributing to the unusual clinical PK properties ([@CR138]). *In vitro* studies revealed far lower vismodegib solubility, 0.0001 mg/ml at higher pH range 6.5--7.4, compared to \~1.0 mg/ml at pH 0.1 ([@CR138]). The impact of solubility was manifested in saturation of oral absorption. There was no increase in mean steady-state concentration (C~ss~), 22.6, 21.3 and 22.0 μM, with increase in oral dose from 150 to 270 and 540 mg, respectively ([@CR139]). The free fraction of vismodegib remained constant at 0.5 ± 0.1% across all dose groups ([@CR139]). However, in a separate study, a 2.6-fold increase in free fraction of vismodegib was reported between a single 150 mg dose (0.25 ± 0.14%) *versus* repeat daily 150 mg doses (0.65 ± 2.9%) ([@CR140]).

Vismodegib plasma protein binding properties were further characterized by isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR) with both procedures showing higher vismodegib--AAG affinity to the human isoform relative to the rat isoform ([@CR141]). By ITC the K~D~ values of vismodegib--AAG were 1.1 and 118 μM in human and rat, respectively. By SPR the K~D~ values of vismodegib--AAG were 13 μM and not detectable in human and rat, respectively, whereas the K~D~ values for vismodegib-albumin were similar in human and rat (120 and 140 μM, respectively). *In vitro* experiments showed a negative correlation between AAG concentration and target engagement, whereby supplementing physiologically relevant concentrations of AAG resulted in a dampening of Hh signaling via *GLI*1-luciferase reporter assay ([@CR141]). There was a high correlation (r^2^ = 0.73, slope 0.48) between AAG and total vismodegib C~ss~ in plasma samples from cancer patients, suggesting the role of plasma protein binding in vismodegib drug disposition ([@CR138]). Perhaps even more compelling was the intra-patient parallel changes in total vismodegib concentrations with changes in AAG. No correlation was found with albumin levels and vismodegib concentrations ([@CR141]). Saturation of AAG has been proposed to be a key determinant in the non-linear PK of vismodegib given that AAG is a high affinity-low capacity protein and near stoichiometric levels of vismodegib and AAG are reported ([@CR140]). Despite the high affinity and resultant low free fraction, there remains sufficient unbound vismodegib available to interact with target to demonstrate pharmacological effect.

In order to understand the mechanism(s) of non-linear PK, healthy human subjects received either a single oral dose or 7 daily oral doses of 150 mg vismodegib, followed by an IV microtracer dose of 10 μg \[^14^C\]-vismodegib 2 h post first or last (day 7) oral dose ([@CR142]). AAG levels were within close range in the two dose groups to eliminate need for correction. CL and V~ss~ values after a single IV dose were 43.4 ml/h and 16.4 l, roughly 10--65-fold lower (depending on number of species employed in model) and 3-fold lower, respectively, compared to preclinical allometric scaling predictions ([@CR137]). Relative to day 1, CL and V~ss~ increased 81% and 63%, respectively on day 7, while t~1/2~ remained unchanged at \~10--11 days. Mean free fraction increased 2.4-fold after 7 days oral dosing (0.79 ± 0.23%) compared to a single dose (0.33 ± 0.12%), a finding consistent with the observations previously described ([@CR140]). Correcting for protein binding of vismodegib, the unbound CL and V~ss~ values were relatively similar on day 1 and 7. Absolute bioavailability was 31.8% following a single oral dose and declined to 7.4% after 7 days of repeat dosing, a finding attributed to slow absorption and limited intestinal solubility ([@CR142]).

Given the non-linear PK with long t~1/2~, a phase Ib clinical study was conducted to determine if vismodegib steady-state concentrations could be maintained with less frequent dosing ([@CR140]). Three oral dosing schedules were evaluated: 150 mg once daily (QD), once weekly (QW) or three times per week (TIW), all after having received a loading dose of vismodegib (150 mg QD, 11 days). After steady-state was achieved for the alternate dose schedules, vismodegib levels declined in the QW and TIW groups relative to QD, however the decline in unbound vismodegib (50% and 80%, respectively) was greater than the decline in total vismodegib (24% and 45%, respectively). Only the QD dose schedule maintained unbound vismodegib concentrations sufficient to achieve target pathway inhibition (IC~95~) of glioma-associated oncogene (*Gli*1) previously described ([@CR143]), therefore the recommended dose and schedule was maintained at 150 mg QD.

One additional point of consideration is the discrepancy between *in vitro* and ex vivo free fraction values reported for vismodegib in human plasma, \~3--4% and \< 0.25--0.79%, respectively ([@CR137],[@CR139],[@CR140],[@CR142]). This discrepancy may be attributed to the collection and storage of blood products as described herein and in recent publications ([@CR129],[@CR130]). Free fraction values increased sharply for AAG-binding drugs when human blood was exposed to plasticizer DEHP; for example, vismodegib free fraction increased from 0.2% when collected in vacutainer (no/minimal plasticizer), to 0.4% and 1.4% when collected and stored in Terumo® bags containing plasticizer for \<1 and 7 days, respectively. Additionally, vismodegib free fraction increased from 0.3 to 2.9% when human plasma was spiked with 800 μM plasticizer, a concentration one could expect to measure in blood after several weeks storage in Terumo® or similar bags.

UCN-01 {#Sec17}
------

UCN-01 (7-hydroxystaurosporine) is a small molecule protein kinase inhibitor. Single agent clinical trials were initiated for multiple oncological indications in the late 1990s, followed by combination studies with other anti-cancer agents. The PK parameters in preclinical species (mouse, rat and dog) ranged as follows: moderate to high CL roughly 30 to 80% hepatic blood flow, high V~ss~ 6 to 17 l/kg, and moderate t~1/2~ from 3 to 12 h ([@CR144]). Clinical PK were not predicted by allometry and exhibited low CL (17 ml/h), low V~ss~ (12 l) and very long t~1/2~ (\>200 h) ([@CR145]). While UCN-01 (1 μg/ml) is considered highly bound to plasma proteins in preclinical species with free fraction ranging from 0.5 to 1.8%, the free fraction was substantially lower in human plasma at \<0.02% ([@CR146]). UCN-01 free fraction was \<0.02% or 6.2% when incubated with physiologically relevant levels of hAAG (1 mg/ml) or albumin (40 mg/ml), respectively, showing the preferential binding to AAG. *In vitro* studies showed marked increase in UCN-01 free fraction with increases in concentration approaching stoichiometric levels of AAG ([@CR147]). The association constant (K~a~) was 799 × 10^6^ l/mol in hAAG (roughly equivalent to K~D~ of 1.25 nM), whereas in dog the K~a~ was \~60-fold lower at 13.2 × 10^6^ l/mol ([@CR147],[@CR148]). Sparreboom *et al.*, further characterized the role of AAG in the PK of UCN-01 ([@CR149]). With an increase in dose ranging from 3.6 to 53 mg/m^2^/day IV infusion over 72 h, there was an increase in CL, 4.13 ml/h to 24.1 ml/h, respectively, a linear increase in V~ss~, 0.113 l to 0.276 l, respectively, and less than proportional (3.5--fold) increase in AUC~∞~, (area under the curve extrapolated to infinity) 7460 to 26,140 mg\*h/l. CL trended (r^2^ = 0.264) with pre-dose AAG levels, despite a relatively small data set (*n* = 39). It is proposed the increase in CL in humans is due, at least in part, to the increase in free fraction once AAG becomes saturated. CL in dogs had demonstrated no dependence on dose from 0.81 to 6.48 mg/kg ([@CR144],[@CR150]), a finding consistent with the notable difference in UCN-01-AAG K~D~ in human *versus* dog.

The K~D~ of hAAG-UCN-01 is roughly 4 orders of magnitude lower compared to K~D~ hAAG-vismodegib ([@CR141]). In addition, UCN-01 does not appear to bind significantly to albumin given the comparable K~D~ values of UCN-01 to AAG *vs* human plasma, 799 *vs* 802 × 10^6^ l/mol, respectively ([@CR147]). Saturation of AAG and the differential affinity to AAG and albumin are likely to contribute to the non-linear PK of UCN-01. As with vismodegib the hAAG-UNC-01 K~D~ differed considerably from that of the preclinical species leading to poor predictive accuracy with allometric methods. UCN-01 has a slow dissociation rate which may reduce V~ss~, further hindering free drug from target interaction ([@CR141]), in contrast to the preclinical observations of high V~ss~, high tumor:plasma ratios, and decline in tumor volume ([@CR144]). UCN-01 has not advanced in the clinic due to unpredictable PK and off-target kinase inhibition ([@CR148]).

Imatinib {#Sec18}
--------

Imatinib is a selective inhibitor of Bcr-Abl, platelet-derived growth factor receptors, and c-KIT receptor tyrosine kinases ([@CR151]). Approval was granted for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors by the FDA in 2001 and 2002. Imatinib-AAG binding is concentration-dependent with a reported K~a~ of 1.7 × 10^6^ l/mol, roughly equivalent to K~D~ of 0.6 μM, while imatinib-albumin binding is considerably weaker with a K~a~ of 3.0 × 10^4^ l/mol, roughly equivalent to K~D~ of 33 μM ([@CR141],[@CR152]). Adding to the complexity is the differential binding of imatinib to various human AAG isoforms, the K~a~ reported above is for the F1-S variant, whereas binding was much weaker for the A variant (unpublished data) ([@CR153]). Separately incubating 24 μM of the AAG variants F1-S and A with 5 μM imatinib resulted in 6% and 18% free fraction, respectively.

Imatinib exhibits linear PK in patients ([@CR154]) with low oral CL ranging from 8 to 12 l/h ([@CR152],[@CR155],[@CR156]), long t~1/2~ of 18 h and high oral bioavailability \>90%. A proportional increase in AUC is observed with oral doses from 25 to 1000 mg. PK parameters are similar between single and repeat doses, showing 1.5- to 2.5-fold accumulation at steady-state. Correlations between imatinib PK and ABCB1 genotype, body weight and AAG levels was shown in patients ([@CR152],[@CR157]). Despite linear PK in total imatinib, a non-linear relationship exists between free fraction and total imatinib concentrations in plasma as a result of high affinity to AAG and \~55-fold weaker affinity to albumin ([@CR158]). Elevated levels of AAG in patients have been linked with delayed or lack of response to imatinib treatment as well as potential resistance mechanism ([@CR159],[@CR160]). In a clinical study with CML patients, approximately half exhibited elevated AAG levels positively correlating with disease progression and white blood count. In the chronic, accelerated, and blast crisis phases of disease, 33, 83 and 75% of these patients, respectively, were increasingly likely to have higher AAG levels.

The impact of the plasticizer DEHP on imatinib free fraction in human plasma was also assessed ([@CR130]). Imatinib free fraction increased from 3.5% when collected in vacutainer (no/minimal plasticizer), to 4.9% and 14.7% when collected and stored in Terumo® bags containing plasticizer for \<1 and 7 days, respectively. Additionally, imatinib free fraction increased from 3.5 to 15.3% when human plasma was spiked with 800 μM plasticizer. The plasticizer-free free fraction values reported by Ingram *et al.* ([@CR130]) are similar (\~5%) to those reported in the package insert (Novartis Pharmaceuticals Corporation, Reference T2017-101).

Pinometostat {#Sec19}
------------

Pinometostat (EPZ-5676) is a first-in-class, small molecule inhibitor of DOT1L and was the first member of the novel histone methyltransferase inhibitor class to enter Phase 1 clinical trials in both adult and pediatric MLL-r leukemia patients. Consensus preclinical predictions across multiple diverse methods suggested pinometostat would be a moderate-to-high CL compound in human with estimates ranging from 8 to 18 ml/min/kg, and species-invariant time approaches showed cross-species congruence in time-concentration profile. However, during early development, the observed CL in human was shown to be markedly lower than that determined in preclinical species. The majority of interspecies scaling and allometric methods over-predicted human CL of pinometostat with fold errors ranging from 4 to 13 ([@CR161]), characterized by 'vertical allometry'. The 3--5-fold difference in free fraction between rat and human provided the basis for the improved prediction using the free fraction corrected intercept (FCIM) method. The unambiguous species difference in CL was not related to qualitative differences in metabolic pathways or routes of elimination, but instead to cross-species differences in plasma protein binding. Concentration dependence in protein binding was observed in human plasma, over a relevant concentration range, which was less apparent in the preclinical species. This, along with *in vitro* kinetic determinations, suggested the saturable binding of pinometostat to AAG. The equilibrium dissociation constant (K~D~) for pinometostat binding to human AAG was measured as 0.24 μM indicating a high affinity interaction. By comparison, prototypical AAG ligands such as dipyridamol, disopyramide and thioridazine have K~D~ values of 15.5, 1.0 and 63 μM respectively. Furthermore, there is the disproportionately higher expression of AAG in human plasma relative to preclinical species, which is likely a contributing factor alone, irrespective of potential species-specific differences in AAG affinity.

Conclusions and Summary {#Sec20}
=======================

It has been suggested when the K~D~ for a given drug-AAG binding is low, and more than a log order lower relative to the K~D~ for albumin, the PK may exhibit non-linearity ([@CR138]). If the drug also has a high affinity to albumin, a high capacity protein, fluctuations in free fraction will be minimal. If the drug has a low affinity to albumin, the non-linear effect may be exacerbated when drug levels are near stoichiometric with AAG, since AAG is a low capacity protein and may become saturated. Given the known differences in abundance and homology across species for AAG, allometric scaling may not be suitable for human PK prediction when there are differences in K~D~, something that can easily be measured *in vitro* now that AAG of preclinical species are commercially available, though still limited in supply. Monitoring AAG and/or free drug concentrations, as well as phenotyping the genetic variants of AAG in patients may be warranted in special circumstances to better understand PK and PD. In Fig. [1](#Fig1){ref-type="fig"}, we propose a flowchart for incorporation of protein binding assessment in drug research and development.

Investigations are ongoing to propose more reliable procedures for the collection and storage of blood for future use in drug free fraction measurements (personal communications with Q^2^ Solutions Holdings, LLC). Special consideration should be given to pregnancy and pediatric populations since AAG levels are substantially lower until about 10 months post-natal. PBPK models have shown predictive utility with incorporation of AAG and albumin levels and drug binding parameters. Quantitative and/or qualitative analysis of AAG may prove useful as a biomarker for disease diagnosis and prognosis, with the potential to serve as discerning criteria to improve likelihood of successful treatment. Since AAG behaves as a positive APR protein in most species (except pig), with levels increasing to varying extents in the disease setting, it may be helpful to consider when comparing PK in healthy *versus* diseased populations or in translating PK/PD relationships across species.

APP

:   Acute phase protein

AAG, AGP, ORM, orosomucoid

:   Alpha-1-acid glycoprotein

AUC

:   Area under curve

CL

:   Clearance

DDI

:   Drug-drug interaction

DEHP

:   Diethylhexyl phthalate

f~u~

:   Fraction unbound

HSA

:   Human serum albumin

IVIVE

:   *In vitro in vivo* extrapolation

K~D~

:   Equilibrium dissociation constant

PD

:   Pharmacodynamics

PK

:   Pharmacokinetics

V~ss~

:   Volume of distribution at steady-state
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